AU2017238644B2 - Methods for treating and preventing C. difficile infection - Google Patents

Methods for treating and preventing C. difficile infection Download PDF

Info

Publication number
AU2017238644B2
AU2017238644B2 AU2017238644A AU2017238644A AU2017238644B2 AU 2017238644 B2 AU2017238644 B2 AU 2017238644B2 AU 2017238644 A AU2017238644 A AU 2017238644A AU 2017238644 A AU2017238644 A AU 2017238644A AU 2017238644 B2 AU2017238644 B2 AU 2017238644B2
Authority
AU
Australia
Prior art keywords
subject
compound
infection
difficile
developing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017238644A
Other languages
English (en)
Other versions
AU2017238644A1 (en
Inventor
Michael P. Draper
S. Ken Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
Original Assignee
Paratek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc filed Critical Paratek Pharmaceuticals Inc
Publication of AU2017238644A1 publication Critical patent/AU2017238644A1/en
Application granted granted Critical
Publication of AU2017238644B2 publication Critical patent/AU2017238644B2/en
Priority to AU2023200798A priority Critical patent/AU2023200798A1/en
Priority to AU2025202020A priority patent/AU2025202020A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017238644A 2016-03-24 2017-03-24 Methods for treating and preventing C. difficile infection Active AU2017238644B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023200798A AU2023200798A1 (en) 2016-03-24 2023-02-14 Methods for treating and preventing C. difficile infection
AU2025202020A AU2025202020A1 (en) 2016-03-24 2025-03-20 Methods for treating and preventing C. difficile infection

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US62/312,996 2016-03-24
US201662320053P 2016-04-08 2016-04-08
US62/320,053 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200798A Division AU2023200798A1 (en) 2016-03-24 2023-02-14 Methods for treating and preventing C. difficile infection

Publications (2)

Publication Number Publication Date
AU2017238644A1 AU2017238644A1 (en) 2018-10-25
AU2017238644B2 true AU2017238644B2 (en) 2022-12-15

Family

ID=59900751

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017238644A Active AU2017238644B2 (en) 2016-03-24 2017-03-24 Methods for treating and preventing C. difficile infection
AU2023200798A Abandoned AU2023200798A1 (en) 2016-03-24 2023-02-14 Methods for treating and preventing C. difficile infection
AU2025202020A Pending AU2025202020A1 (en) 2016-03-24 2025-03-20 Methods for treating and preventing C. difficile infection

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023200798A Abandoned AU2023200798A1 (en) 2016-03-24 2023-02-14 Methods for treating and preventing C. difficile infection
AU2025202020A Pending AU2025202020A1 (en) 2016-03-24 2025-03-20 Methods for treating and preventing C. difficile infection

Country Status (13)

Country Link
US (3) US20170319603A1 (OSRAM)
EP (1) EP3432891A4 (OSRAM)
JP (3) JP7458706B2 (OSRAM)
CN (2) CN119454720A (OSRAM)
AU (3) AU2017238644B2 (OSRAM)
BR (2) BR112018069303A2 (OSRAM)
CA (1) CA3018872A1 (OSRAM)
MX (2) MX2018011413A (OSRAM)
MY (1) MY197627A (OSRAM)
PH (1) PH12018502020A1 (OSRAM)
RU (1) RU2751509C1 (OSRAM)
SG (2) SG11201808246SA (OSRAM)
WO (1) WO2017165729A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119454720A (zh) * 2016-03-24 2025-02-18 帕拉特克Spv2有限责任公司 用于治疗和预防艰难梭菌感染的方法
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
RU2019113715A (ru) * 2016-11-01 2020-12-03 Паратек Фармасьютикалс, Инк. 9-аминометилминоциклиновые соединения и их применение для лечениия внебольничной бактериальной пневмонии(вбп)
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
BR112021004057A2 (pt) * 2018-09-04 2021-05-25 Paratek Pharmaceuticals, Inc. métodos de tratar ou prevenir uma infecção micobacteriana, de tratar ou prevenir, de controlar ou reduzir o avanço, severidade ou efeitos de uma doença micobacteriana, tuberculose, lepra, bronquiectasia, doença pulmonar cavitária, linfadenite, uma doença de tecido mole, granuloma de aquário, úlcera de buruli, uma doença ocular e doença óssea em um indivíduo em necessidade dos mesmos, e, métodos de tratar um indivíduo com uma doença pulmonar e de tratar um indivíduo com uma condição imunossuprimida.
US11730776B2 (en) * 2018-10-10 2023-08-22 Nutri Co., Ltd. Preventive and/or therapeutic agent for clostridium difficile infection
WO2021252876A1 (en) * 2020-06-11 2021-12-16 Paratek Pharmaceuticals, Inc. Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113399A1 (en) * 2008-05-19 2010-05-06 Paratek Pharmaceuticals, Inc. Salts and Polymorphs of a Tetracycline Compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2324392A (en) * 1991-07-24 1993-02-23 Procter & Gamble Company, The Antimicrobial treatment methods and compositions
EA201000496A1 (ru) * 2000-07-07 2010-10-29 Трастис Оф Тафтс Коллидж Замещенное соединение миноциклина, способ получения замещенных соединений миноциклина (варианты)
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332549A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Novel tetracyclines and their use in medicine
AU2006331685A1 (en) * 2005-12-22 2007-07-05 Wyeth Methods of treating gastrointestinal tract infections with tigecycline
WO2007087416A2 (en) * 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
EP2396029A4 (en) * 2009-02-11 2012-08-08 Cedars Sinai Medical Center ANTIBIOTIC THERAPY FOR REDUCING THE PROBABILITY OF THE DEVELOPMENT OF POST-INFECTIOUS REIZDARY SYNDROME
CN102947334B (zh) * 2010-04-15 2017-12-26 普罗杰尼克制药股份有限公司 用于治疗艰难梭菌相关感染和疾病的抗体
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
CN119454720A (zh) * 2016-03-24 2025-02-18 帕拉特克Spv2有限责任公司 用于治疗和预防艰难梭菌感染的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113399A1 (en) * 2008-05-19 2010-05-06 Paratek Pharmaceuticals, Inc. Salts and Polymorphs of a Tetracycline Compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LARSON K.C. et al.: Annals of Pharmacotherapy, 2011, vol. 45, no. 7-8, pp. 1005-1010 *
MACONE A.B. et al.: Antimicrobial Agents & Chemotherapy, 2014, vol. 58, no. 2, pp. 1127-1135 *

Also Published As

Publication number Publication date
EP3432891A1 (en) 2019-01-30
JP2022115985A (ja) 2022-08-09
US20200281948A1 (en) 2020-09-10
BR122024000249A2 (pt) 2024-02-27
US20170319603A1 (en) 2017-11-09
AU2017238644A1 (en) 2018-10-25
EP3432891A4 (en) 2019-10-30
US20250049819A1 (en) 2025-02-13
AU2025202020A1 (en) 2025-04-10
CA3018872A1 (en) 2017-09-28
AU2023200798A1 (en) 2023-03-09
MY197627A (en) 2023-06-29
CN109152789A (zh) 2019-01-04
WO2017165729A1 (en) 2017-09-28
MX2023004969A (es) 2023-05-24
CN119454720A (zh) 2025-02-18
BR112018069303A2 (pt) 2019-01-22
RU2751509C1 (ru) 2021-07-14
JP2019509318A (ja) 2019-04-04
PH12018502020A1 (en) 2019-07-15
SG11201808246SA (en) 2018-10-30
JP7458706B2 (ja) 2024-04-01
SG10201913559VA (en) 2020-02-27
JP2024023187A (ja) 2024-02-21
MX2018011413A (es) 2019-01-10

Similar Documents

Publication Publication Date Title
US20250049819A1 (en) Methods for treating and preventing c. difficile infection
Di Bella et al. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options
Shad et al. Shigella sonnei: virulence and antibiotic resistance
US10857164B2 (en) Halogenated salicylanilides for treating Clostridium infections
RU2412241C2 (ru) Способ профилактики желудочно- кишечных заболеваний у животных или людей, способ лечения желудочно-кишечных заболеваний у животных или людей и лекарственное средство для лечения или профилактики желудочно-кишечных заболеваний у животных или людей
Kee Clostridium difficile infection in older adults: a review and update on its management
Hedge et al. New advances in the treatment of Clostridium difficile infection (CDI)
WO2010021930A1 (en) Prevention and treatment of mrsa infections with chitosan-derivatives
Gao et al. Ability of Clostridium butyricum to inhibit Escherichia coli-induced apoptosis in chicken embryo intestinal cells
Cecil Clostridium difficile: changing epidemiology, treatment and infection prevention measures
Manga et al. Evaluation of changes induced in the probiotic Escherichia coli M17 following recurrent exposure to antimicrobials
Wilcox Clostridium difficile infection and pseudomembranous colitis
Mathias et al. Management of adult Clostridium difficile digestive contaminations: a literature review
Sirirak et al. Eleutherine americana: A candidate for the control of Campylobacter species
CN116515663A (zh) 乳酸菌组合物及其用于制备抑制抗药性肠杆菌的口服组合物的用途
WO2020079051A1 (en) Compounds for treatment of microbial infection
Riddle et al. Trends in Clostridium difficile disease: epidemiology and intervention
Singh et al. Antimicrobial agents in agriculture and their implications in antimicrobial resistance
Etifa The efficacy of probiotics in modulating Clostridium difficile spore germination, growth and toxin production in an in vitro human gut model
Tanaka et al. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept
Thenmozhi et al. FOOD BORNE PATHOGENS AND ITS PATHOPHYSIOLOGY
Chen Novel therapeutic approaches targeting Clostridium difficile
Nsofor et al. Antibiotic susceptibility pattern of Escherichia coli isolates from human and animal specimens in Owerri, Nigeria
Thakur et al. Antimicrobial resistance in gram positive and gram negative bacteria progress and challenges
Alam Biological Evaluation Of Membrane-active Compounds As Treatment For Clostridium Difficile Infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)